OpenAI’s latest move into biotech began with the acquisition of Orchestra Bio, a four-year-old startup that built AI agents for the operational grind behind drug development. The companies did not disclose financial terms, although Orchestra had reportedly raised about $20 million by 2025 from investors including Andreessen Horowitz, Atria and 8VC.¹

Orchestra’s platform was designed to help biopharma teams coordinate a process that can be derailed by mundane but costly problems: tracking budgets, monitoring studies, managing development timelines and flagging clinical-trial scheduling issues. OpenAI described it as “a platform that helps biopharma teams coordinate the complex process of drug development.”²

The acquisition now places Orchestra’s staff and technology inside Rosalind, OpenAI’s life-sciences suite and its Rosalind Workbench tool for planning experiments and analyzing results. The stated ambition is to connect scientific findings with the practical decisions needed to move a possible treatment forward. OpenAI says new medicines commonly take 10 to 15 years to develop, a timetable it hopes AI can compress.³

The deal lands amid a broader race to turn general-purpose AI into industry infrastructure. OpenAI already counts Moderna and Novo Nordisk among Rosalind customers, while rival Anthropic has launched Claude Science and, according to reporting, bought biotech startup Coefficient Bio for roughly $400 million in April.¹

For OpenAI, Orchestra is a building block in a larger life-sciences bet. For startups in the field, it is another signal that the biggest model makers may not merely supply the tools—they may buy, build or outgrow the specialists using them.